C
CERE

Covestor’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Covestor’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-287
Closed -$12K – 2909
2024
Q2 		$12K Buy
287
+1
+0.3% +$42 0.01% 1444
2024
Q1 		$12K Sell
286
-9
-3% -$378 0.01% 1483
2023
Q4 		$13K Hold
295
– – 0.01% 1406
2023
Q3 		$6K Sell
295
-1
-0.3% -$25 ﹤0.01% 1707
2023
Q2 		$9K Sell
296
-2
-0.7% -$61 0.01% 1547
2023
Q1 		$7K Sell
298
-3
-1% -$88 0.01% 1495
2022
Q4 		$10K Sell
301
-1
-0.3% -$28 0.01% 1349
2022
Q3 		$9K Sell
302
-3
-1% -$89 0.01% 1325
2022
Q2 		$8K Sell
305
-4
-1% -$114 0.01% 1302
2022
Q1 		$11K Buy
309
+124
+67% +$3.62K 0.01% 1298
2021
Q4 		$6K Buy
+185
New +$6.53K 0.01% 1270

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Covestor's CERE Position: Q3 2024 in Review

Covestor sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 287 shares — an estimated $12K sold.

Covestor first reported a position in CERE in Q4 2021 and held it in 11 quarters. The position peaked at $13K in Q4 2023. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Covestor reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Covestor sold 287 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $12K.
  • Covestor first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2021 and held it in 11 quarters.
  • Covestor's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $13K in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Covestor's 13F filing for Q3 2024, filed 1 Nov 2024.